Breast Cancer in Young Women

2019 ◽  
Author(s):  
Lisa A Newman
Keyword(s):  
Breast Cancer ◽  
Young Women ◽  
Triple Negative ◽  
Breast Conserving Surgery ◽  
The United States ◽  
Population Based ◽  
Incidence Rates ◽  
Disease Stage ◽  
Locoregional Therapy ◽  
Key Words Breast

The perception that breast cancer in young women is a growing problem in the United States is based on the fact that young women represent a demographic that has enlarged substantially over the past few decades. Population-based data actually reveal relatively stable incidence rates for breast cancer among women in the premenopausal age range. Young women are more likely to be diagnosed with biologically aggressive phenotypes such as triple-negative and HER2/neu-overexpressing breast cancer. Outcomes are optimized by treatment plans focusing on disease stage and targeted to phenotype. Locoregional therapy for breast cancer in young women should be based on patient preferences and disease pattern (as in older patients); young women with breast cancer can be managed safely with breast-conserving surgery. This review contains 3 figures, 2 tables, and 50 references. Key Words: breast cancer, fertility, ovarian suppression, premenopausal, young women; triple negative breast cancer

Breast Cancer in Young Women

2019 ◽  
Author(s):  
Lisa A Newman
Keyword(s):  
Breast Cancer ◽  
Young Women ◽  
Triple Negative ◽  
Breast Conserving Surgery ◽  
The United States ◽  
Population Based ◽  
Incidence Rates ◽  
Disease Stage ◽  
Locoregional Therapy ◽  
Key Words Breast

The perception that breast cancer in young women is a growing problem in the United States is based on the fact that young women represent a demographic that has enlarged substantially over the past few decades. Population-based data actually reveal relatively stable incidence rates for breast cancer among women in the premenopausal age range. Young women are more likely to be diagnosed with biologically aggressive phenotypes such as triple-negative and HER2/neu-overexpressing breast cancer. Outcomes are optimized by treatment plans focusing on disease stage and targeted to phenotype. Locoregional therapy for breast cancer in young women should be based on patient preferences and disease pattern (as in older patients); young women with breast cancer can be managed safely with breast-conserving surgery. This review contains 3 figures, 2 tables, and 50 references. Key Words: breast cancer, fertility, ovarian suppression, premenopausal, young women; triple negative breast cancer

Receipt of locoregional therapy among young women with breast cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1100-1100
Author(s):  
Rachel A. Freedman ◽  
Katherine S. Virgo ◽  
Julia Labadie ◽  
Ann H. Partridge ◽  
Nancy Lynn Keating
Keyword(s):  
Breast Cancer ◽  
Young Women ◽  
Breast Conserving Surgery ◽  
National Cancer Data Base ◽  
Locoregional Therapy ◽  
Adjuvant Radiation ◽  
Optimal Care ◽  
Younger Women ◽  
Cancer Data ◽  
To Receive

1100 Background: Although younger women with breast cancer have the most to gain from receipt of optimal care, few data are available regarding their receipt of locoregional breast cancer treatments. Methods: We identified 318,083 women aged 18-64 who were diagnosed with invasive breast cancer at hospitals reporting to the National Cancer Data Base, a large national cancer registry, during 2004-2008. We used multivariable logistic regression to assess the association of patient age with mastectomy vs. breast-conserving surgery (BCS), radiation with BCS, and post-mastectomy radiation (PMRT) with varying indications, adjusting for patient and tumor characteristics, area-level socioeconomic status, and insurance. Results: Overall, 4% of women were aged ≤35 and 7% were aged 36-40. Women aged ≤35 were significantly more likely to have mastectomy than BCS compared with women aged 56-60 (57% vs. 35%, adjusted odds ratio [OR] 1.97; 95% Confidence Interval [CI] 1.87-2.07) but were less likely to receive radiation if BCS was performed (69% vs. 80%, OR 0.77; 95% CI 0.73-0.82). For those who underwent mastectomy, although overall rates of PMRT receipt were low, women aged ≤35 were more likely to receive postmastectomy radiation (PMRT) despite the presence or absence of clinical indications for PMRT (OR 1.11; 95% CI 1.01-1.22 for strong indications, OR 1.71; 95% CI 1.53-1.91 for borderline indications, and OR 1.49; 95% CI 1.28-1.73 for no indications [all vs. ages 56-60]). Conclusions: Young women with breast cancer may not be receiving optimal locoregional therapy. We observed lower odds of radiation after BCS but higher odds of PMRT for young women regardless of indications for PMRT. Efforts are needed to further understand and improve the receipt of appropriate adjuvant radiation therapy among young women to improve their disease-free and overall survival.

Understanding international genomic diversity for breast cancer: Comparison of molecular subtypes of breast cancer in very young women (age ≤ 35) between Izmir (Western Turkey) and Boston (Massachusetts, USA).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e12509-e12509
Author(s):  
Burcak Karaca ◽  
Tracy Ann Battaglia ◽  
Naomi Ko ◽  
Moly McCoy ◽  
Hatice Yasdik ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Genetic Diversity ◽  
Young Women ◽  
Triple Negative ◽  
Molecular Subtypes ◽  
The United States ◽  
Genomic Diversity ◽  
Molecular Subtyping ◽  
Luminal B ◽  
Her 2

e12509 Background: One in forty women is diagnosed with breast cancer at a very young age (≤35 years). Studies suggest breast cancer molecular subtypes are different in young women, with a higher prevalence of triple negative and HER-2+ disease. Objective: Explore the impact of genetic diversity on molecular subtyping of very young breast cancer patients in geographically and ethnically diverse populations: Turkey and the United States. Methods: A retrospective analysis of women ≤35 years of age diagnosed with breast cancer from 1999-2011 at Ege University Faculty of Medicine (EUFM) and Boston Medical Center (BMC). Data were collected and abstracted from hospital cancer registries and electronic medical records. Molecular subtyping was based on immunohistochemical evaluation of estrogen, progesterone receptors, Ki-67, and HER2/neu. Bivariate analysis was conducted using Chi-Square and Fisher’s Exact tests. Results: There were 206 and 45 patients from EUFM and BMC, respectively. Mean age at diagnosis was 31.4±3; most were white (87%), parous (70%), had breast fed (74%), and no1st degree relatives with breast cancer (92%). BMC patients were younger (31.7±3 v. 29.9±3 p=.0006) and more racially diverse (0% v. 60% black/hispanic p <.0001). There were clinicopathological differences between EUFM and BMC, including: histological subtype (IDC 68% v. 93% p=.02), HER-2/neu positivity (60% v. 16% p <.0001), and Ki67 ≥15% (54% v. 83% p=.008). Missing data precluded subtyping in 25% and 22% of women at EUFM and BMC. Of subtypes determined, prevalence was the same; however, EUFM had more Luminal B and less Triple negative patients then BMC. Conclusions: Population-level similarities and proportional distinctions exist in molecular subtypes of breast cancer for women ≤35 years. In both countries, Luminal B and triple negative sybtypes were most common suggesting younger age rather than genetic diversity is an important determinant of molecular subtyping. [Table: see text]

scholarly journals The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-14 ◽  
Author(s):  
Jacob Y. Shin ◽  
Lisa A. Kachnic ◽  
Ariel E. Hirsch
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Dissection ◽  
Male Breast Cancer ◽  
The United States ◽  
Primary Treatment ◽  
Population Based ◽  
Male Breast ◽  
Disease Stage ◽  
Node Dissection

The purpose of this study is to compare the racial differences in treatment and overall survival (OS) of male breast cancer (MBC) patients. Data were extracted from the NCI SEER database that included population-based registries from 1988 to 2010 and analyzed using SPSS 20.0. 4,279 MBC patients were identified. 3,266 (76.3%) patients were White, 552 (12.9%) Black, 246 (5.7%) Hispanic, and 215 (5.0%) Asian. Black patients were more likely to be diagnosed at younger age(P<0.001), have advanced stage disease(P=0.001), and be unmarried(P<0.001)and less likely to undergo lymph node dissection(P=0.006). When stratified by stage, there was no difference in receipt of primary treatment by race. The 5-year OS for White, Black, Hispanic, and Asian races was 73.8%, 66.3%, 74.0%, and 85.3%(P<0.001). This significant worse 5-year OS for Blacks persisted regardless of age, stage II or III disease, and grade 2 or 3 disease. On multivariate analysis, Black race was a significant independent prognostic factor for worse OS. Blacks were less likely to receive lymph node dissection of which patients may derive benefit, though we did not observe receipt of primary treatment, after stratifying for disease stage, to be an underlying factor contributing to racial outcome differences.

scholarly journals Subtype-Specific Breast Cancer Incidence Rates in Black versus White Men in the United States

2019 ◽  
Vol 4 (1) ◽  
Author(s):  
Hyuna Sung ◽  
Carol DeSantis ◽  
Ahmedin Jemal
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Black Women ◽  
Racial Differences ◽  
White Women ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Breast Cancer Incidence ◽  
The United States ◽  
Incidence Rates

Abstract Compared with white women, black women have higher incidence rates for triple-negative breast cancer but lower rates for hormone receptor (HR)–positive cancers in the United States. Whether similar racial difference occurs in male breast cancer is unclear. We examined racial differences in incidence rates of breast cancer subtypes defined by HR and human epidermal growth factor receptor 2 (HER2) by sex using nationwide data from 2010 to 2016. Among men, rates were higher in blacks than whites for all subtypes, with the black-to-white incidence rate ratios of 1.41 (95% confidence interval [CI ]= 1.32 to 1.50) for HR+/HER-, 1.65 (95% CI = 1.40 to 1.93) for HR+/HER2+, 2.62 (95% CI = 1.48 to 4.43) for HR-/HER2+, and 2.27 (95% CI = 1.67 to 3.03) for triple-negative subtype. Conversely, among women, rates in blacks were 21% lower for HR+/HER2- and comparable for HR+/HER2+ but 29% and 93% higher for HR-/HER2+ and triple-negative subtypes, respectively. Future studies are needed to identify contributing factors to the dissimilar racial patterns in breast cancer subtype incidence between men and women.

Sign in / Sign up

Export Citation Format

Share Document